Ryvu Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Ryvu Therapeutics (formerly Selvita) is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in precision oncology.
The company is headquartered in Kraków, Poland. Ryvu Therapeuctis was founded in 2007 and currently employs 150 scientists, including 80 Ph.Ds. Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncology.
Lead candidate, SEL120, is a selective CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, currently in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in Phase 1/2 clinical development for the treatment of AML.
Early pipeline candidates include candidates developed in the area of kinases, cancer metabolism, synthetic lethality and immuno-oncology.
Ticker:
RVU
Exchange:
Warsaw Stoch Exchange
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Poland
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
SEL24/MEN1703
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
6
Speaker
photo
Business Alliance Director
Ryvu Therapeutics